logo
Worried About Social Security in 2025? A Pro Financial Planner Shares Key Things To Know

Worried About Social Security in 2025? A Pro Financial Planner Shares Key Things To Know

Yahoo7 days ago
Many Americans are feeling uneasy about the future of Social Security. While the average monthly Social Security benefit is now over $2,000, some experts also predict that the Social Security trust fund will deplete its reserves within the decade.
In an episode of the 'Future Rich' podcast, Barbara Ginty, CFP, reassured listeners that while Social Security isn't going away, it does face pressures that require thoughtful planning.
Read Next:
Learn More:
Here are some things you should know, as well as seven things to do if you're worried about Social Security.
Check Your Earnings Record
Ginty said to qualify for Social Security, workers need at least 40 work credits, which amounts to roughly 10 years of employment.
Without meeting this minimum, they are not eligible for retirement benefits. Reviewing one's earnings record on the Social Security website regularly helps to ensure that reported income is accurate and that no credits are missing.
Find Out:
Know How Benefits Are Calculated
Social Security calculates retirement benefits based on a person's highest 35 years of earnings.
Years with no reported income, such as time spent in school, caregiving or unemployment, can reduce the monthly benefit unless replaced by higher-earning years later.
'Those zero years will fall off,' Ginty said. 'They're going to take the highest of your 35 years of earnings in which you paid into Social Security.'
Understand Who Can Claim
Social Security offers more than just retirement benefits. Spouses, former spouses, widows, widowers, surviving ex-spouses, minor children of deceased workers and people with disabilities may all be eligible.
'There's a few different ways you can collect on Social Security, and that's where this can get a bit confusing,' Ginty said.
Understanding these different claiming options is key to maximizing lifetime benefits.
'I think it is a lot more important as a household to consider what the benefits look like and how you're going to collect. Versus a single individual, where you have only one benefit available, as a household, there's two benefits,' Ginty said.
Report Your Income
Workers who are paid in cash or 'off the books' and do not report their income will not accumulate Social Security credits.
'If you don't plan accordingly, you could miss out on, or you most likely will miss out on, your Social Security,' Ginty said. 'You could also miss out on Medicare, so you want to make sure you are on the books.'
Ginty said that failing to contribute to the system could result in being ineligible for future benefits, including retirement, disability and survivor payments.
Learn How It's Funded
Social Security is a 'pay-as-you-go' program funded through payroll taxes. This means today's benefits are largely funded through payroll taxes collected from today's workers.
Employees contribute 6.2% of their wages toward Social Security and 1.45% toward Medicare, with employers matching both amounts.
'Now, if you're self-employed, you are responsible for the full 15.3%,' Ginty said. 'You need to be covering both sides of that, meaning … if you are self-employed, you're the employee and you're the employer. So you have to do both sides of it.'
Have a Collection Strategy
Claiming Social Security as soon as benefits become available may not always be the best decision.
Ginty said having a collection strategy, particularly for married couples, helps maximize total benefits over two lifetimes and secure greater financial stability in retirement.
'I do believe it is important to consider a strategy with Social Security, not to just collect as soon as you're eligible, but to think about why you're collecting and how you're collecting, and how it will affect yourself and or your household,' she explained.
Don't Count on Social Security Alone
Social Security was never intended to serve as a retiree's sole source of income.
'It was intended to be a supplement for retirees,' Ginty said. 'It … has never been meant to be your sole source of income. Sadly, for some retirees today, it is the single largest source of income.'
Ginty said that individuals aim to save at least 15% of their income for retirement to supplement their Social Security benefits, especially given rising life expectancies and the program's future uncertainty.
'I like to see your own savings being greater than what is being mandated by the government,' Ginty said. 'Remember, it is meant to be a supplement to your retirement. You don't want it to be your single largest source of income in retirement. That's just not as comfortable.'
More From GOBankingRates
Warren Buffett: 10 Things Poor People Waste Money On
This article originally appeared on GOBankingRates.com: Worried About Social Security in 2025? A Pro Financial Planner Shares Key Things To Know
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating
Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating

Yahoo

time4 minutes ago

  • Yahoo

Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating

Spotify Technology S.A. (NYSE:SPOT) is among the 13 Best Global Stocks to Buy Right Now. On July 11, Keybanc lifted the stock's price target to $860 from $640, while maintaining an Overweight rating for its shares. The adjustment represents significant upside potential, given its share price of $674.46 at the close on July 23. Copyright: dennizn / 123RF Stock Photo The firm said that it expects Spotify Technology S.A. (NYSE:SPOT)'s second-quarter results and guidance for the third quarter to contain some variability related to foreign exchange, seasonal gross margin dynamics, and social charges. The analyst has advised investors to buy any near-term dips and reiterated that its core thesis remains intact. Keybanc believes that music is under-monetized in a price inflationary market with favorable competitive dynamics and several initiatives that support high-teens revenue growth. In other news, Deutsche Bank on Wednesday also raised Spotify Technology S.A. (NYSE:SPOT)'s target price to $775 from $700 and maintained a Buy rating for its shares. The Luxembourg-based company, which provides digital music-streaming services worldwide, has seen impressive returns in 2025, gaining 51% year-to-date. While we acknowledge the potential of SPOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds and 13 Best Booming Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

Yahoo

time4 minutes ago

  • Yahoo

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

Yahoo

time4 minutes ago

  • Yahoo

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store